Cargando…

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban

Unlike vitamin K antagonists (VKAs), the new oral anticoagulants (NOACs)—direct thrombin inhibitor, dabigatran, and direct activated factor X inhibitors, rivaroxaban, and apixaban—do not require routine INR monitoring. Compared to VKAs, they possess relatively rapid onset of action and short halfliv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ru San, Tan, Chan, Mark Yan Yee, Wee Siong, Teo, Kok Foo, Tang, Kheng Siang, Ng, Lee, Sze Huar, Chi Keong, Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444866/ https://www.ncbi.nlm.nih.gov/pubmed/22997573 http://dx.doi.org/10.1155/2012/108983

Ejemplares similares

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
por: Rutherford, Ole-Christian W, et al.
Publicado: (2020)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
por: Pillarisetti, Jayasree, et al.
Publicado: (2020)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins
por: Jakimczuk, Aleksandra, et al.
Publicado: (2022)

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban
por: Winkle, Roger A., et al.
Publicado: (2014)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
por: Lai, Chao‐Lun, et al.
Publicado: (2017)

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Effects of Apixaban, Rivaroxaban, Dabigatran and Enoxaparin on Histopathology and Laboratory Parameters in Achilles Tendon Injury: An in vivo Study
por: Avci, Sema, et al.
Publicado: (2021)

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
por: Freyburger, Geneviève, et al.
Publicado: (2015)

Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
por: Ansell, Jack, et al.
Publicado: (2021)

Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system
por: Villines, Todd C, et al.
Publicado: (2019)

Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS—Method Development, Validation, and Application
por: Lindahl, Sofia, et al.
Publicado: (2018)

Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers
por: Ćelap, Ivana, et al.
Publicado: (2020)

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
por: Slavik, L., et al.
Publicado: (2019)

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2015)

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
por: Mezue, Kenechukwu, et al.
Publicado: (2017)

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
por: Lip, Gregory Y. H., et al.
Publicado: (2016)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
por: Yin, Lu, et al.
Publicado: (2022)

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2017)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users
por: McHorney, Colleen A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7a48rpgtnd5ahajtvt6vl51h44